1Kraeber-Bodéré F,Rousseau C,Bodet-Milin C,et al.Targeting,toxicity,and efficacy of 2-step,pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131Ⅰ-labeled bivalent hapten in a phase Ⅰ optimization clinical trial[J].Nucl Med,2006,47(2):247-255.